Janney Capital analyst Paul Knight believes the post-earnings selloff in shares of Brooks Automation is attributable to disappointment from some investors that no Life Science spinoff news was announced. However, he thinks, and he said the company thinks, that it is too early for a spin, though he added that the company did telegraph potential timing and he believes the likelihood of a spinoff will increase as Life Science margins and cash flow increase. Knight, who sees compelling value in Brooks shares, keeps a Buy rating and $40 fair value estimate on the stock.